View Older Stories View More Recent Stories

Sep 30, 2026 07:10AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Sep 30, 2026 04:34AM Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens as AZN Invests $2B in Strategic Equity
Sep 29, 2026 07:16AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
Sep 29, 2026 05:38AM Goldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Sep 29, 2026 05:16AM Summit Therapeutics plc (SMMT) PT Raised to $30 at Jefferies
Sep 29, 2026 05:14AM Stifel Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Sep 29, 2026 05:03AM Summit Therapeutics gets $2B AstraZeneca investment, Citi raises target
Sep 28, 2026 05:33PM AstraZeneca invests $2B in Summit Therapeutics preferred shares
Sep 25, 2026 04:17AM Summit Therapeutics (SMMT) Reiterated at Market Outperform by Citizens
Sep 23, 2026 06:51AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Sep 22, 2026 07:47AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
Sep 22, 2026 06:01AM Ivonescimab trial data in biliary tract cancer to be shown at ESMO 2026
Sep 16, 2026 08:47AM UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Sep 15, 2026 06:01AM Summit ivonescimab shows consistent survival data across regions at WCLC
Sep 13, 2026 07:47PM Ivonescimab cuts death risk 27% vs. pembrolizumab in lung cancer
Sep 9, 2026 06:45AM Jefferies Upgrades Summit Therapeutics plc (SMMT) to Buy
Sep 8, 2026 09:12AM UBS Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Sep 3, 2026 06:57AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Sep 1, 2026 06:54AM Summit Therapeutics plc (SMMT) Reiterated at Overweight by Cantor Fitzgerald
Aug 26, 2026 07:09AM Guggenheim Reiterates Buy Rating on Summit Therapeutics plc (SMMT)
Aug 26, 2026 06:40AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Aug 25, 2026 06:39PM Akeso's ivonescimab beats durvalumab in biliary tract cancer trial
Aug 25, 2026 07:02AM Summit Therapeutics publishes HARMONi Phase III lung cancer trial data
Aug 25, 2026 02:25AM Bernstein SocGen Group Upgrades Summit Therapeutics plc (SMMT) to Market Perform
Aug 19, 2026 06:49AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Aug 12, 2026 09:22AM China approves ivonescimab plus chemo for squamous NSCLC
Aug 12, 2026 06:34AM Leerink Upgrades Summit Therapeutics plc (SMMT) to Market Perform
Aug 6, 2026 06:55AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Jul 27, 2026 06:32AM Summit Therapeutics (SMMT) spreader of 10K contracts of January 10 and 25 calls trade
Jul 24, 2026 10:18AM Summit Therapeutics plc (SMMT) PT Lowered to $38 at Stifel, But 'Fundamental Conviction Intact'
Jul 24, 2026 07:51AM Summit Therapeutics plc (SMMT) PT Lowered to $38 at Guggenheim
Jul 24, 2026 06:53AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald After Q2 Results
Jul 23, 2026 05:42PM Summit Therapeutics (SMMT) Reports In-Line Q2 EPS
Jul 23, 2026 04:25PM Summit Therapeutics: substantial doubt about our ability to continue as a going concern
Jul 23, 2026 04:06PM Summit Therapeutics posts Q2 loss, reports ivonescimab trial data
Jul 23, 2026 07:10AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Jul 22, 2026 04:30PM Arcus and Summit team up to test kidney cancer drug combo
Jul 22, 2026 06:30AM Summit ivonescimab shows OS hazard ratio of 0.76 in lung cancer trial
Jul 16, 2026 06:48AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Jul 15, 2026 07:37AM H.C. Wainwright Reiterates Neutral Rating on Summit Therapeutics plc (SMMT)
Jun 22, 2026 09:26AM Summit Therapeutics plc (SMMT) PT Raised to $9.80 at Bernstein SocGen Group
Jun 12, 2026 12:37PM Summit Therapeutics co-CEO Robert Duggan acquires 3.81 million shares
Jun 3, 2026 06:51AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
Jun 1, 2026 08:23AM Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
Jun 1, 2026 07:55AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
Jun 1, 2026 07:41AM Summit Therapeutics (SMMT) Reiterated at Buy by Stifel on HARMONi-6 'Win'
Jun 1, 2026 02:53AM Summit's ivonescimab shows survival benefit in lung cancer trial
May 26, 2026 09:14AM Bernstein SocGen Reiterates Underperform Rating on Summit Therapeutics plc (SMMT)
May 22, 2026 07:28AM Summit Therapeutics (SMMT) Reiterated at Overweight by Cantor Fitzgerald
May 22, 2026 06:35AM H.C. Wainwright Downgrades Summit Therapeutics plc (SMMT) to Neutral
View More Recent Stories View Older Stories